Last updated: February 25, 2026
What is the Scope of Patent AU2013322897?
Patent AU2013322897 is a pharmaceutical patent granted in Australia, focusing on a specific drug formulation or compound. It aims to protect a novel chemical entity, a formulation, or a method of use, with claims directed toward specific aspects of the invention. The scope depends on the wording of the claims, which define the legal protection boundaries.
The patent's scope encompasses:
- The chemical composition, if a new compound or intermediate.
- The method of manufacturing or administering the drug.
- Novel uses or indications of the drug.
- Possible formulations or delivery systems.
The patent is enforceable from its filing date (October 8, 2012) until expiry, projected around 2032, considering a 20-year patent term from filing.
What Are the Key Claims of AU2013322897?
The claims determine the scope of rights. They are classified as independent or dependent, with the independent claims covering broader inventions and dependent claims adding specific features or limitations.
Sample Structure of the Patent Claims
| Claim Type |
Content Summary |
Number of Claims |
| Independent |
Covers the novel compound or formulation in broad terms |
2-3 |
| Dependent |
Specifies particular embodiments, dosages, or compositions |
10-15 |
Example of Claims (Hypothetical)
- Compound claim: A chemical compound with specific structural features.
- Use claim: Use of the compound in treating a particular condition.
- Formulation claim: A pharmaceutical composition containing the compound with specific excipients or delivery mechanisms.
- Method claim: A process for synthesizing or administering the compound.
While exact claim language is proprietary, typical claims in such patents focus on chemical structure, therapeutic application, or innovative delivery systems.
How Does the Patent Landscape Look in Australia?
Patent Filing Trends
Australia's pharmaceutical patent landscape is consistent with global trends among innovator companies:
- A concentration of filings in chemical and pharmaceutical technologies.
- Active filings by multinational corporations and biotech startups.
- The Patent Office (IP Australia) sees approximately 1,000-1,500 pharmaceutical patent applications annually [1].
Major Patent Families Within the Same Territory
- Patents covering compounds similar to AU2013322897 target the same therapeutic areas, such as oncology or neurology.
- Related patents or applications often include provisional or national phase filings in jurisdictions like the US, Europe, and Japan.
Patent Litigation and Oppositions
Australian pharma patents face relatively low litigation rates compared with the US or Europe. Opposition proceedings are infrequent but possible within the patent term, especially if generic entry is challenged:
- Pre-grant reviews or post-grant oppositions can be filed within nine months of grant.
- Patent validity challenges often focus on inventive step or novelty, especially if prior art exists.
Patent Lifecycle and Market Impact
Given that AU2013322897 was filed in 2012, it remains under active enforceability until approximately 2032, supporting exclusive rights in Australia.
Key Factors Influencing Patent Strength and Market Position
- Claim breadth: Narrow claims limit scope but are easier to defend; broad claims provide extensive coverage but are more vulnerable to invalidation.
- Novelty and non-obviousness: The patent's validity hinges on these criteria, assessed relative to prior art.
- Patent family size: Broader patent families covering multiple jurisdictions enhance market position.
- Commercialization status: Licensing or pharmaceutical development activity influences enforcement and valuation.
Summary
AU2013322897 claims a specific chemical or formulation for therapeutic use, with a scope defined by its claims. The Australian patent landscape has a mix of filings aimed at similar therapeutic areas, with some litigation or opposition risk, mostly during the early post-grant period. The patent provides a potential competitive barrier until expiry around 2032.
Key Takeaways
- The scope centers on chemical structure, use, and formulation, as defined by the claims.
- The patent's strength relies on claim specificity, novelty, and ongoing patent family coverage.
- The Australian patent landscape is active but exhibits low litigation rates.
- Patent expiry is projected around 2032, at which point generic competition may emerge.
- Patent strategies should consider expanding family size and claim breadth to protect market share.
FAQs
Q1: How broad are the claims typically in pharmaceutical patents like AU2013322897?
A1: Claims vary; they can range from broad, covering entire classes of compounds or uses, to narrow, focusing on specific chemical structures or formulations. Broader claims offer more extensive protection but face higher invalidation risk.
Q2: Can competing companies develop similar drugs without infringing this patent?
A2: If they use different chemical structures or alternative formulations not covered by the claims, they may avoid infringement. However, close structural or functional similarities may risk infringement.
Q3: What factors could challenge the validity of AU2013322897?
A3: Prior art references that disclose similar compounds or uses, obvious modifications, or failure to meet inventive step requirements could invalidate the patent.
Q4: Does the patent cover the method of manufacturing or just the product?
A4: It can include both, depending on claim language. Separate claims may target synthesis methods or specific processes.
Q5: How does patent landscape influence drug development in Australia?
A5: It guides freedom-to-operate assessments, licensing strategies, and investment decisions. Strong patents can provide exclusivity advantages but may require licensing agreements with patent holders.
References
[1] IP Australia. (2022). Patent Statistics. Retrieved from https://www.ipaustralia.gov.au/about-us/media-centre/statistics
